
Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s, Obesity
By Bruce Y. Lee, Senior Contributor
Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebrand
This story was published by Forbes. Read the full article on their site.
Read the full story at forbes.com(opens in a new tab)





